Company Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.
The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses.
Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
| Country | United States |
| Founded | 2001 |
| IPO Date | Jan 26, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Thomas Zindrick |
Contact Details
Address: 2625 Townsgate Road, Suite 230 Westlake Village, California 91361 United States | |
| Phone | 805 267 9889 |
| Website | genelux.com |
Stock Details
| Ticker Symbol | GNLX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001231457 |
| CUSIP Number | 36870H103 |
| ISIN Number | US36870H1032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas D. Zindrick J.D. | Chairman, Chief Executive Officer and President |
| Matthew Pulisic M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Dr. Joseph Cappello Ph.D. | Chief Technical Officer |
| Dr. Yong Yu Ph.D. | Chief Scientific Officer |
| Eric Groen J.D. | General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development |
| Ralph Smalling B.Sc. | Vice President and Head of Regulatory Affairs |
| Dr. Jason B. Litten M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 22, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 144 | Filing |
| May 7, 2026 | 10-Q | Quarterly Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 19, 2026 | 424B5 | Filing |
| Mar 19, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2026 | 8-K | Current Report |
| Mar 19, 2026 | 10-K | Annual Report |